0001209191-20-024672.txt : 20200416 0001209191-20-024672.hdr.sgml : 20200416 20200416173321 ACCESSION NUMBER: 0001209191-20-024672 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200414 FILED AS OF DATE: 20200416 DATE AS OF CHANGE: 20200416 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCANGOS GEORGE A CENTRAL INDEX KEY: 0001202102 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 20797241 MAIL ADDRESS: STREET 1: C/O EXELIXIS INC STREET 2: 170 HARBOR WAY CITY: SAN FRANCISCO STATE: CA ZIP: 94083 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-04-14 0 0001706431 Vir Biotechnology, Inc. VIR 0001202102 SCANGOS GEORGE A C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO CA 94158 1 1 0 0 President and CEO Common Stock 2020-04-14 4 J 0 236806 29.56 D 1907329 I See footnote Common Stock 2020-04-14 4 J 0 236806 29.56 A 4713559 D This transaction represents a substitution of assets in which 236,806 shares of the Issuer's common stock were transferred to the reporting person from the George A. Scangos 2018 Annuity Trust dated August 30, 2018 (the "GRAT") in exchange for other assets. The reporting person was the beneficial owner of the shares while they were held by the GRAT and remains the beneficial owner of the shares following their withdrawal from the GRAT. The reporting person believes that the transfer was exempt under Rule 16a-13 under the Securities Exchange Act of 1934. Represents the average of the reported high and low per share prices for the Issuer's common stock on the date of the transaction. The shares are held in the name of the GRAT, of which the reporting person and his spouse are trustees. The total number of shares of common stock reported herein as directly owned includes 78,087 shares previously reported as indirectly owned through the GRAT and subsequently distributed to the reporting person in accordance with the terms of the GRAT. /s/ Howard Horn, Attorney-in-Fact 2020-04-16